http://www.ncbi.nlm.nih.gov/pubmed/21127304
7.Bots ML, Launer LJ, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Arch Intern Med. 1999 Jan 11;159(1):38-44. http://www.ncbi.nlm.nih.gov/pubmed/9892328
8.Saposnik G, Ray JG, Sheridan P, McQueen M, et al. Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009 Apr;40(4):1365-72. http://www.ncbi.nlm.nih.gov/pubmed/19228852
9.Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research,; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Feb;42(2):517-84.